NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage
NeOnc Technologies outlined plans for a proposed pivotal trial of NEO100, its intranasal brain-cancer therapy designed to bypass the blood-brain barrier, targeting roughly 500 patients across 30 hospitals in three countries. The promotional piece recaps its December 2025 clinical update citing radiographic remission in six of 25 patients (~24%) and notes NEO212 completed Phase 1 dose-escalation, with an FDA meeting scheduled November 17 to discuss potential Phase 2 design. The release also flags trading dynamics — about 877,000 shares short (~5.6 days to cover) with the stock recovering from ~$2.50 to above $3.
Key figures
- Drug Name
- NEO100
- Phase Of Trial
- proposed pivotal trial (pre-Phase 3); NEO212 completed Phase 1 dose-escalation
- Stock low
- $2.50
- Days to cover
- 5.6 days
- Fda meeting date
- November 17
- Planned trial sites
- 30
- Short interest shares
- 877000
- Planned trial patients
- 500
- Planned trial countries
- 3
- Radiographic remission rate
- 6 of 25 patients (~24%)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.